JPRN-UMIN000035180已完成未知
Biomarker analysis for alectinib and bevacizumab in ALK-positive NSCLC - NLCTG1501-BM
iigata University0 个研究点目标入组 12 人开始时间: 2018年12月8日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 12
研究概览
简要总结
There was no difference in PFS or OS by serum biomarkers, but there was a trend toward longer PFS in patients with some biomarker positivity.
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •According to NLCTG1501
研究者
相似试验
已完成
不适用
Biomarker study for afatinib plus bevacizimabon-small cell lung cancer with EGFR mutationsJPRN-UMIN000032489Okayama University100
招募中
2 期
TAS-CC5 Studycolorectal cancerJPRN-jRCT1031220613Takeshi Yamada105
招募中
不适用
Examination of the relationship between biomarkers in nasal discharge during initial wheezing and the onset of asthma in early childhoodBronchial asthmaJPRN-UMIN000044655Dokkyo Medical University Hospital148
已完成
不适用
Study of the relation between biomarker patterns and the incidence of recurrent coronary events during 1-year follow-up in patients who were hospitalised for an acute coronary syndrome; BIOMarker Study to identify the Acute risk of a Coronary Syndrome (BIOMArCS)coronary artery disease'furring' of the coronary arteries1001108210003216NL-OMON43706Erasmus MC, Universitair Medisch Centrum Rotterdam900
暂停
不适用
Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)Colorectal NeoplasmsNCT03743428Shenzhen People's Hospital40